Les Laboratoires Servier SAS - Strategic SWOT Analysis Review
Description
Les Laboratoires Servier SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Les Laboratoires Servier SAS (Servier) is advancing therapeutic solutions in oncology, cardio-metabolism, venous diseases, and neurology, with a focus on areas where treatment options are limited, such as digestive cancers, gliomas, and hematological cancers. The company offers a wide range of medicines in cardiometabolism, including Atorduo, Coversyl, and Daflon; in oncology, such as Asparlas, Lonsurf, and Onivyde; and in neurology, including Arcalion, Stablon, and Valdoxan. Its research and development efforts focus on immuno-oncology, targeted therapies, and neurological treatments using antisense oligonucleotides and small molecules. The company operates through production sites and research centers in Boston, Denmark, and Paris-Saclay. Servier is headquartered in Suresnes, France.
Les Laboratoires Servier SAS Key Recent Developments
Apr 01,2026: Servier Discusses Changes in the Healthcare Sector at Global Industry
Mar 18,2026: Patient Organizations Address Treatment Adherence
Mar 13,2026: Servier CMO’s offering at the Tianjin site
Mar 09,2026: kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
Reasons to Buy
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Les Laboratoires Servier SAS (Servier) is advancing therapeutic solutions in oncology, cardio-metabolism, venous diseases, and neurology, with a focus on areas where treatment options are limited, such as digestive cancers, gliomas, and hematological cancers. The company offers a wide range of medicines in cardiometabolism, including Atorduo, Coversyl, and Daflon; in oncology, such as Asparlas, Lonsurf, and Onivyde; and in neurology, including Arcalion, Stablon, and Valdoxan. Its research and development efforts focus on immuno-oncology, targeted therapies, and neurological treatments using antisense oligonucleotides and small molecules. The company operates through production sites and research centers in Boston, Denmark, and Paris-Saclay. Servier is headquartered in Suresnes, France.
Les Laboratoires Servier SAS Key Recent Developments
Apr 01,2026: Servier Discusses Changes in the Healthcare Sector at Global Industry
Mar 18,2026: Patient Organizations Address Treatment Adherence
Mar 13,2026: Servier CMO’s offering at the Tianjin site
Mar 09,2026: kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
48 Pages
- Section 1 - About the Company
- Les Laboratoires Servier SAS - Key Facts
- Les Laboratoires Servier SAS - Key Employees
- Les Laboratoires Servier SAS - Key Employee Biographies
- Les Laboratoires Servier SAS - Major Products and Services
- Les Laboratoires Servier SAS - History
- Les Laboratoires Servier SAS - Company Statement
- Les Laboratoires Servier SAS - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Les Laboratoires Servier SAS - Business Description
- R&D Overview
- Les Laboratoires Servier SAS - Corporate Strategy
- Les Laboratoires Servier SAS - SWOT Analysis
- SWOT Analysis - Overview
- Les Laboratoires Servier SAS - Strengths
- Les Laboratoires Servier SAS - Weaknesses
- Les Laboratoires Servier SAS - Opportunities
- Les Laboratoires Servier SAS - Threats
- Les Laboratoires Servier SAS - Key Competitors
- Section 3 – Company’s Lifesciences Financial Deals and Alliances
- Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Les Laboratoires Servier SAS, Recent Deals Summary
- Section 4 – Company’s Recent Developments
- Apr 01, 2026: Servier Discusses Changes in the Healthcare Sector at Global Industry
- Mar 18, 2026: Patient Organizations Address Treatment Adherence
- Mar 13, 2026: Servier CMO’s offering at the Tianjin site
- Mar 09, 2026: kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
- Feb 16, 2026: Servier Releases 2024/2025 Annual Report
- Jan 27, 2026: Servier Posts Strong 2024/25 Results and Confirms 2030 Forecasts
- Jan 27, 2026: Servier Delivers Solid Performance in 2024/25 and Confirms Its Forecasts for 2030
- Jan 05, 2026: Insilico and Servier announce $888m oncology research agreement
- Sep 30, 2025: Peptisystems Supports Servier’s First Step Into In-House Oligonucleotide Synthesis
- Sep 09, 2025: Servier to acquire potential Fragile X syndrome treatment from Kaerus
- Section 5 – Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Les Laboratoires Servier SAS, Key Facts
- Les Laboratoires Servier SAS, Key Employees
- Les Laboratoires Servier SAS, Key Employee Biographies
- Les Laboratoires Servier SAS, Major Products and Services
- Les Laboratoires Servier SAS, History
- Les Laboratoires Servier SAS, Subsidiaries
- Les Laboratoires Servier SAS, Key Competitors
- Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Les Laboratoires Servier SAS, Recent Deals Summary
- List of Figures
- Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

